 Lausanne, Switzerland, November 2 3 , 202 2 AC Immune SA NASDAQ: ACIU, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology SupraAntigen, and of its anti-Tau and anti-Abeta investigational candidates, at the 15th Clinical Trials on Alzheimers Disease CTAD conference in San Francisco, California United States and online, on November 29 December 2, 2022. 